Garadacimab

Garadacimab is an activated Factor XII (FXIIa) inhibitor used to prevent attacks of hereditary angioedema. No information is available on the clinical use of garadacimab during breastfeeding. Because garadacimab is a large protein molecule with a molecular weight of about 146,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[3]